Abstract. Prehypertensive losartan treatment may lead to long-term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs). However, the underlying mechanism has yet to be fully elucidated. The aim of the present study was to investigate the expression of angiotensin type 1 receptor-associated protein (ATRAP/Agtrap) and methylation of the Agtrap gene in the myocardium following the withdrawal of treatment. Four-week-old SHRs were randomly divided into three groups, and were treated with saline, amlodipine or losartan, respectively, for 6 weeks. Wistar Kyoto rats (WKYs) were used as a control. All rats were followed up regularly until they reached the age of 32 weeks. Systolic blood pressure (SBP), left ventricular mass/body weight (LVM/BW), and cardiac fibrosis and structure were measured. The mRNA and protein expression of ATRAP in the myocardium were determined using reverse transcription-quantitative polymerase chain reaction and western blot analysis. Methylation of the Agtrap promoter was detected by bisulfite pyrosequencing. Reduced levels of SBP, LVM/BW, cardiac fibrosis and interventricular septum thickness were determined to be maintained only in prehypertensive losartan-treated SHRs. Whereas, an increased expression of ATRAP mRNA and protein, and hypomethylation of the Agtrap promoter in the myocardium, were demonstrated only in the losartan-treated SHRs. In conclusion, the results of the present study suggested that the hypomethylation of Agtrap accompanying upregulation of ATRAP expression in the myocardium is associated with the long-term inhibition of LVH in SHRs with prehypertensive losartan treatment.
Introduction
Hypertension-associated left ventricular hypertrophy (LVH) is considered to be an independent risk factor of adverse cardiovascular events, including arrhythmia, myocardial infarction, congestive heart failure, stroke and kidney failure (1) (2) (3) (4) (5) (6) . In spontaneously hypertensive rats (SHRs), prehypertensive treatment with losartan, a renin-angiotensin system (RAS) inhibitor, may prevent the development of LVH in the long term. By contrast, the calcium-channel blocker, amlodipine, another class of antihypertensive drug, fails to maintain the beneficial effects following the withdrawal of treatment. Beyond prolongation of the blood pressure-lowering effect, a decrease in the levels of certain RAS components in the myocardium, including angiotensin ΙΙ (Ang ΙΙ) and Ang II type 1 receptor (AT1R), may explain the inhibition of LVH induced by early losartan treatment (7) . It is well established that RAS comprises a number of components, and the various components collaborate to regulate homeostasis and pathogenesis of the cardiovascular system (8) . Therefore, it is reasonable to hypothesize that changes occur in the other components of RAS in the myocardium of losartan-treated SHRs.
AT1R-associated protein (ATRAP/Agtrap), a newly identified component of RAS, specifically binds to AT1R, promotes internalization of the receptor, and downregulates the AT1R-mediated signaling pathway (9) . Overexpression of ATRAP attenuates cardiomyocyte hypertrophy in vitro (10) , reduces oxidative stress and inflammation in local tissue in vivo (11, 12) , and inhibits LVH in chronic Ang ΙΙ-infused mice (13) . Furthermore, an imbalance of AT1R and ATRAP in the myocardium is associated with the development of hypertension-associated LVH (14) . However, there are few previously published studies on ATRAP expression in the myocardium of prehypertensive treated SHRs (15) .
In the present study, prehypertensive SHRs were treated with losartan or amlodipine. In addition to LVM/BW, cardiac fibrosis and structure, the expression of ATRAP was observed in the myocardium of adult rats. It is well known that the Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats expression of genes may be regulated by genomic variation or epigenetic modification. The latter includes DNA methylation. Therefore, an aim of the present study was to measure methylation of the Agtrap promoter in the myocardium of treated SHRs. 
Materials and methods

Animals
Measurement of blood pressure and evaluation of LVH.
Systolic blood pressure (SBP) of the conscious rats was measured using the tail-cuff method (Softron BP-98A; Softron TM , Beijing, China) as previously described (16) , and was recorded as the mean of three consecutive readings. Body weight (BW) was measured using a balance prior to sacrifice. The chests of the rats were opened, their hearts were removed and blotted dry following sacrifice. The left ventricular mass (LVM), including the ventricular septum, was weighed, and LVM/BW was calculated to determine cardiac hypertrophy.
Determination of cardiac fibrosis. Cardiac fibrosis was measured as previously described in our laboratory (17) . Briefly, the hearts were immersed into 4% formalin for 24 h, embedded in paraffin and cut into 4-µm sections for Sirius Red staining. Sections were observed under a light microscope (CX31; Olympus Corp., Tokyo, Japan). Images were analyzed using Image Pro Plus 6.0 software (Media Cybernetics. Inc., Rockville, MD, USA). The collagen volume fraction (CVF) in the ventricular septum, an index of cardiac fibrosis, was determined as the percentage of the Sirius Red-stained area/total ventricular septum area.
Echocardiography for cardiac structure and function. Rats were anesthetized as described above, and transthoracic echocardiography was subsequently performed in the left lateral decubitus position. An M-mode echocardiogram was obtained from the long-axis view of the left ventricle (LV) using a vivid 7 echocardiographic system (GE Healthcare, Piscataway, NJ, USA) with a 10 MHz probe. The left ventricular end-diastolic dimension (LVEDD), end-diastolic interventricular septum thickness (IVSTd) and left ventricular ejection fraction (LVEF) were measured according to the guidelines of the American Society of Echocardiography (18) .
Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) for ATRAP mRNA. Total RNA from the LV tissue was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. Total RNA (2 µg) was reverse-transcribed into complementary DNA (cDNA) using a RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific, Inc.). RT-qPCR was performed using SYBR Green PCR Master mix (Takara Bio, Inc., Otsu, Japan) and detected using an ABI Prism7000 sequence detection system (Applied Biosystems Life Technologies, Foster City, CA, USA). Thermocycler conditions consisted of an initial activation step at 95˚C (30 min), followed by a three-step PCR program of 95˚C (for 10 sec), 60˚C (for 31 sec) and 72˚C (30 sec) for 40 cycles for primer denaturation, annealing and extension, respectively. The mRNA level was quantified by calculating the values of the Δ cycle threshold (ΔC q ) by normalizing the average C q value compared with its internal control (Gapdh), and then calculating 2 -ΔΔCq (19) . The primer sequences were as follows:
Western blot analysis for the expression of ATRAP protein.
Western blotting was performed as previously described in our laboratory, although with minor modifications (20) . Briefly, the total protein in LV was extracted, and the concentrations were determined using a bicinchoninic acid protein concentration determination kit (Beyotime Institute of Biotechnology, Beijing, China). Aliquots of 80 µg protein lysates extracted from the hearts were separated using 10% SDS-PAGE gels, electro-transferred onto polyvinylidene fluoride membranes, blocked with 5% non-fat milk in TBS containing 0.05% Tween-20 (TBST), and the protein was probed with anti-ATRAP antibody (1:200; cat. no. sc134652; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or anti-β-actin antibody (1:1,000; cat. no. sc1616; Santa Cruz Biotechnology, Inc) overnight at 4˚C. After 3 washes with TBST for 5 min, the membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1:5,000; cat. nos. ZB-2301; ZB-2305; OriGene Technologies, Inc., Beijing, China). Following another 3 washes with TBST for 10 min, protein bands were visualized using electrochemiluminescence on high-performance chemiluminescence film (Lulong Biotech Co., Ltd., Xiamen, China), and were quantified using Image Pro Plus version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA).
CpG island analysis of the Agtrap promoter region.
CpG islands in the Agtrap promoter region were analyzed using the online tool, Methprimer (http://www.urogene. org/methprimer/index.html) with parameters window100, shift1, observed CpG/expected CpG≥0.60 and GC%≥50.0%.
Bisulfite-specific polymerase chain reaction (BSP-PCR) and DNA sequencing for methylation of the Agtrap promoter.
Genomic DNA in LV was extracted using a GenElute Mammalian Genomic DNA mini-Prep kit (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) following the manufacturer's protocol, and was subsequently subjected to treatment with the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). The bisulfite-modified DNA was amplified by PCR using BSP-specific primer pairs [GeneTech (Shanghai) Co., Ltd., Shanghai, China] under the following conditions: 95˚C for 3 min; followed by 40 cycles of 95˚C for 15 sec, 54˚C for 30 sec, 72˚C for 30 sec; and 72˚C for 5 min. The PCR products were sequenced using a PyroMark ID sequencer (Biotage AB, Uppsala, Sweden) according to the manufacturer's protocol. The percentage of methylated CpG at each site was quantified using the Pyro Q-CpG software, version 1.0.9 (Biotage AB). The primers for BSP and DNA sequencing were as follows: Agtrap: 5'-TGGTAGAGGTTTAGGTAGTAGTAG GAGT-3' (forward); 5'-biotin-CCAACTCCAAAACAAACT TCCT-3' . (reverse); and 5'-GTTTTGTAGTAAGGGTAAT-3' (sequencing).
Statistical analysis. Statistical analysis was performed using SPSS version, 17.0 (SPSS, Inc., Chicago, IL, USA). Continuous data are presented as the means ± standard deviation. Differences between groups were compared by one-way analysis of variance, followed by a least significant difference t-test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.
Results
Prehypertensive losartan treatment reduces SBP in adult
SHRs. SBP in the SHR group increased with age, to a maximum for the rats at 20 weeks of age, and this higher level was maintained until the rats were 32 weeks old. However, there was no change of SBP with age in the WKY group. In addition, SBP was lower in the SHR-Aml and SHR-Los groups compared with SHR before the rats reached the age of 20 weeks (for the 20-week-old rats in the three groups: SHR-Aml, 193±16 mmHg and SHR-Los, 172±14 mmHg vs. SHR, 219±14 mmHg; P<0.001). From the age of 24 weeks onwards, SBP in the SHR-Aml group increased to the level of the SHR group (32 weeks old: SHR-Aml, 218±12 mmHg vs. SHR, 224±7 mmHg; P=0.281); however, the rats treated with losartan had a significantly lower SBP until they reached 32 weeks of age (32 weeks old: SHR-Los, 197±17 mmHg vs. SHR, 224±7 mmHg; P<0.001) (Fig. 1) . Fig. 2A) and CVF (Fig. 2B ) in the SHR group were significantly higher compared with the age-matched WKY group (LVM/BW at 32 weeks of age: SHR 3.38±0.12 mg/g vs. WKY 2.38±0.16 mg/g, P<0.001; CVF, SHR 9.64±0.95% vs. WKY 2.39±0.12%, P<0.001), and a marked decrease was observed in SHR-Los compared with the SHR group throughout the study period (LVM/BW at 32 weeks of age: SHR-Los, 2.86±0.21 mg/g vs. SHR, 3.38±0.12 mg/g, P<0.001; CVF, SHR-Los 5.76±0.99 % vs. SHR 9.64±0.95%, P<0.001) ( Fig. 2A and B) . LVM/BW in the SHR-Aml group was lower than SHR at 20 weeks of age (SHR-Aml 2.85±0.20 mg/g vs. SHR 3.06±0.13 mg/g P=0.024); however, there was no difference between the two groups at 14 and 32 weeks of age (32 weeks old: SHR-Aml 3.35±0.23 mg/g vs. SHR 3.38±0.12 mg/g: P=0.690) (Fig. 2A) . CVF in the SHR-Aml group was comparable with that of the SHR group at the same ages throughout the study period (32 weeks old: P=0.590) (Fig. 2B) .
Prehypertensive losartan treatment inhibits LVH and cardiac fibrosis. LVM/BW (
The effect of prehypertensive losartan treatment on cardiac structure and function. The data obtained are shown in Table I elevated compared with SHR (at 32 weeks of age: SHR-Los, 0.79±0.11 vs. SHR, 0.63±0.08; P=0.014) (Fig. 3) . As shown in Fig. 4 , no significant differences were observed in the protein level of ATRAP at 14 weeks among the four groups of rats (P=0.057). However, at the ages of 20 weeks and 32 weeks, the protein level in the SHR group was decreased compared with age-matched WKY (at 32 weeks of age: SHR 0.34±0.10 vs. WKY 1.04±0.10, P<0.001), and losartan-treated SHRs demonstrated an increased protein level compared with the SHR group (at 32 weeks of age: SHR-Los, 0.69±0.10 vs. SHR0.34±0.10; P<0.001. No significant differences were observed in the expression levels of ATRAP mRNA and protein between the SHR and age-matched SHR-Aml groups throughout the study period (mRNA at 32 weeks of age: P=0.883; protein, P=0.638).
Prehypertensive losartan treatment decreases the methylation of Agtrap promoter in the myocardium. One CpG island was identified in the vicinity of the transcription start site (TSS) of Agtrap between the upstream -132 bp and downstream +144 bp (Fig. 5A) . As shown in Fig. 5B , changes in the methylation level among the four groups of the rats were observed at the -120, -117, -85 and -65 bp sites in the CpG islands, but not at the other CpG sites (Fig. 5B) . The methylation level at the -120 bp site was higher in the SHR group than in WKY throughout the study period (at 32 weeks old: SHR 17.6±2.3% vs. WKY 4.8±0.9% P<0.001), and although no significant differences were observed between the SHR and SHR-Aml groups (at 32 weeks old: SHR 17.6±2.3% vs. SHR-Aml 16.4±2.0%, P=0.187), the level was reduced in the age-matched SHR-Los group (at 32 weeks old: SHR 17.6±2.3% vs. SHR-Los 6.4±1.5%, P<0.001) (Fig. 5C ). Similar changes were identified at the -117, -85 and -65 bp sites; furthermore, the methylation levels at the three target sites in the SHR-Los group were comparable with those of the age-matched WKY group (-117, -85 and -65 bp at 32 weeks old: P=0.247; Fig. 5D-F) .
Discussion
In the present study, it has been demonstrated that prehypertensive losartan treatment was more effective than amlodipine in preventing the progression of LVH and cardiac fibrosis in adult SHRs. It was also shown that the beneficial effect of early losartan treatment was associated with the upregulation of ATRAP expression and hypomethylation of the Agtrap promoter in the myocardium. Previous evidence has shown that prehypertensive patients are more likely to progress to manifest hypertension than patients with optimal or normal blood pressure. Certain prehypertensive patients may even be at an increased risk of mortality from cardiovascular disease (21, 22) . However, it has yet to be determined whether early treatment is able to prevent the pathogenesis of hypertension. The present study has revealed that prehypertensive losartan treatment was able to reduce SBP, LVM/BW and CVF in adult SHRs. The TRial Of Preventing HYpertension ('TROPHY') and Prevention of hypertension with the angiotensin-converting enzyme inhibitor, ramipril ('PHARAO') trials demonstrated that prehypertensive treatment with RAS inhibitor over a relatively short time period reduced the risk of incident hypertension (23, 24) . In addition, animal studies that featured early L-arginine and antioxidant supplements or captopril demonstrated a delay in the increase of blood pressure in adult SHRs (25) (26) (27) . Nevertheless, the administration of the antihypertensive drug, amlodipine, or treatment with a β-blocker led to no effect on long-term blood pressure in SHRs (28) . These findings suggested that, although prehypertensive treatment is an attractive alternative, the use of proper medicines remains important.
In the present study, the upregulation of ATRAP expression was revealed in losartan-treated SHRs, suggesting that ATRAP may be partly responsible for the beneficial effects elicited by early losartan treatment on LVH. It may be hypothesized that ATRAP inhibited LVH through several potential pathways. One possibility is that ATRAP downregulated p38 mitogen-activated protein kinase (p38-MAPK) whereas p38-MAPK could mediate negative inotropic action (29, 30) . Secondly, ATRAP may inhibit the signal transducer and activator of transcription 3 (STAT3) signaling pathway (29) . It has been reported that the STAT3 signaling pathway is associated with an increase in microtubule stabilization, and a decrease in contractility in the myocardium (31) . Therefore, ATRAP may increase the contractility of cardiomyocytes. Finally, it is also possible that ATRAP blocks the calcineurin/nuclear factor of activated T cells (NFAT) pathway (32) and, consequently, gene expression associated with cardiomyocyte hypertrophy is downregulated. Taken together, ATRAP may attenuate compensatory LVH through different pathways.
LVH occurs due to the adaptation to pressure or volume overload with an overactivation of protein turnover. Protein balance is regulated by synthesis and degradation. Li et al (29) demonstrated that the level of ATRAP was controlled by proteasome degradation, whereas protein synthesis may be regulated at the translational and transcriptional levels, including via the process of methylation modification. It was predicted that one CpG island would be located in the vicinity of the TSS of the Agtrap promoter. Our data have further demonstrated that methylation of the Agtrap promoter was negatively correlated with the expression of ATRAP mRNA, suggesting that ATRAP expression may be regulated by methylation modification. A burgeoning body of evidence has shown that the methylation of specific genes is involved in the pathogenesis of genetic hypertension and associated target organ damage (33, 34) . For example, Cho et al (35) revealed that methylation of the Na + -K + -2Cl -co-transporter 1 was decreased in the aorta and heart of adult SHRs, and Pei et al (36) demonstrated that hypomethylation of ATRAP in the aorta and mesenteric artery of SHRs was accompanied by increased blood pressure. Furthermore, Watson et al demonstrated that the DNA methylation inhibitor, 5-azacytidine, was able to prevent the development of LVH in SHRs (37) . Therefore, these studies suggested that prehypertensive losartan treatment reduces the DNA methylation level of Agtrap, resulting in the upregulation of ATRAP expression in the myocardium, which consequently leads to an inhibition of the development of LVH in adult SHRs.
Methylation is catalyzed by DNA methyltransferases (38) , and it may be triggered by oxidative stress (39) . Further studies are required to better understand the mechanism of the hypomethylation of Agtrap.
In conclusion, the results presented in the current study have demonstrated that hypomethylation of Agtrap in the myocardium was associated with an increased expression of ATRAP and an attenuation of LVH in prehypertensive losartan-treated SHRs, providing a novel insight into the beneficial effects elicited by an early RAS inhibitor.
